the pleural effusions. Abdominal CT scan revealed the disappearance of most and the reduction in size of the remaining splenic lesions, indicating that the splenic abnormalities were secondary to disseminated tuberculosis.
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia Leukemia (2006) 20, 381-383. doi:10.1038/sj.leu.2404060; published online 8 December 2005 Activating mutations in genes encoding for signaling molecules are frequently detected in human malignancies. In acute leukemias these mutations may act as cooperating events conferring a proliferative advantage to hematopoietic progenitors. A number of the same genetic lesions that deregulate proliferation in acute myeloid (AML) and/or lymphoblastic leukemia (ALL) such as activating mutations in RAS and PTPN11 or the BCR/ABL fusions also play integral roles in the pathogenesis of myeloproliferative disorders (MPD).
JAK2 is one of the four mammalian Janus kinases (JAK) that, after activation of cytokine or growth factor receptors, are recruited and activated through trans-phosphorylation. Following their activation, JAK proteins phosphorylate specific tyrosine residues on the receptor, which then bind to signal transducer and activator of transcription (STAT) proteins that further activate downstream signaling events.
1 Recently, several groups described a clonal and recurrent mutation, c.1849G4T (V617F), in the pseudo-kinase (JH2)-domain of the JAK2 gene in most patients with polycythemia vera and in a substantial proportion of patients with essential thrombocythemia, and chronic idiopathic myelofibrosis (reviewed in Shannon and Van Etten 2 ). This gain-of-function mutation, which is frequently duplicated by mitotic recombination, predicts to disrupt the auto-inhibition of the catalytic domain by the JH2-domain. The mutation confers cytokine independent growth in vitro and induces erythrocytosis in a murine model (reviewed in Shannon and Van Etten 2 ). In more recent studies, the same somatic mutation has been identified in a small percentage of patients with AML (AML-M7 and AML after MPD), chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, idiopatic hypereosinophilic syndrome, systemic mastocytosis, chronic neutrophilic leukemia and, rarely, in patients with myelodysplastic syndrome. [3] [4] [5] [6] Two JAK2 fusion proteins with constitutive kinase activity, TEL-JAK2 and PSM1-JAK2, have been identified in patients with ALL. 1, 7 On the basis of these data, we employed denaturing high-performance liquid chromatography to screen for the activating JAK2 mutation, c.1849G4T (V617F), in genomic DNA extracted from diagnostic bone marrows from 286 children with ALL treated on trial ALL-BFM 2000. This large cohort allowed us to analyze a sufficient number of patients from different biologic ALL subgroups. Clinical characteristics of the patients included in this study are depicted in Table 1 . Of note, this trial does not include infants with ALL below the age of 1 year, who are treated on a separate protocol. To identify samples with duplication of the mutant allele, samples were diluted with wild-type DNA in a second analysis. In none of the 286 samples, we uncovered the c.1849G4T mutation. However, in a bone marrow DNA specimen from a 3-year-old girl with precursor-B-ALL, we detected a transition c.1832T4C, predicting a leucine to serine substitution in the JH2 domain of JAK2. This variation was absent in remission marrow and is thus likely to represent a pathologic mutation (Figure 1 ). Molecular analyses excluded three fusion genes, BCR/ABL, MLL/AF4 and TEL/AML in the same diagnostic specimen.
Together with three very recent studies, in which the presence of the JAK2V617F allele was excluded in 20 176, and 128 patients with ALL, respectively, 3, 4, 8 our data strongly suggest that the JAK2V617F allele does not contribute to the pathogenesis of this disease in children. Our genetic data, however, suggest that other mutations, such as L611S, rarely contribute to the pathogenesis of childhood ALL. According to our findings, extended screening of JAK2 in childhood ALL may be warranted. 
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Figure 1
Two chromatograms of uncloned and cloned DNA show a heterozygous transition c.1832T4C, predicting a leucine to serine substitution in the JH2 domain of JAK2. This alteration was identified in the diagnostic bone marrow of one child with acute lymphoblastic leukemia. As shown in the third chromatogram DNA extracted from this patient's remission marrow did not harbor this lesion.
